Alternatives to Tyenne If You Can't Fill Your Prescription

Tyenne (tocilizumab-aazg) is a highly effective treatment for rheumatoid arthritis, giant cell arteritis, and related inflammatory conditions. But specialty biologic access isn't always straightforward — insurance denials, prior authorization delays, or specialty pharmacy logistics can temporarily prevent you from getting your dose.

If you can't access Tyenne, there are alternatives your doctor may consider. This article is meant to inform — not replace — the conversation you should have with your rheumatologist. Never switch medications without medical supervision.

Other Tocilizumab Products (Same Drug, Different Brands)

The simplest alternative to Tyenne is another product containing tocilizumab — the same active molecule in a different brand:

Actemra (tocilizumab): The original reference biologic made by Genentech/Roche. It has more approved indications than Tyenne (including systemic sclerosis-associated interstitial lung disease). Since the launch of biosimilars, some insurers have moved patients from Actemra to Tyenne; a denial of Tyenne may still allow Actemra if your plan's step therapy requires the reference product.

Tofidence (tocilizumab-bavi): The first FDA-approved tocilizumab biosimilar (approved September 2023, launched May 2024). Available in IV formulation only. Made by Biogen/Bio-Thera.

Avtozma (tocilizumab-anoh): The third tocilizumab biosimilar, FDA approved January 2025 by Celltrion, launched October 2025. Available in both IV and SC formulations.

Switching between tocilizumab products is generally straightforward, but always requires a new prescription and insurance review. Your doctor can initiate this process.

Kevzara (Sarilumab): Another IL-6 Receptor Antagonist

Kevzara (sarilumab) is also an interleukin-6 (IL-6) receptor antagonist — the same mechanism as Tyenne. It is FDA-approved for moderately to severely active rheumatoid arthritis in adults who have had an inadequate response to one or more DMARDs.

Key differences: Kevzara is only available as a subcutaneous injection (200 mg every two weeks or 150 mg every two weeks) and is not approved for GCA, SJIA, PJIA, CRS, or COVID-19 — indications where Tyenne has FDA approval. If you're on Tyenne specifically for RA, Kevzara may be a clinical alternative worth discussing with your rheumatologist.

TNF Inhibitors: A Different Biologic Class for RA

If you cannot access any IL-6 inhibitor, your doctor may consider switching to a TNF inhibitor — a different class of biologic that also treats RA. These are often the first biologic tried for RA and are widely available in biosimilar forms. Examples include:

Adalimumab (Humira) and its many biosimilars (Amjevita, Hadlima, Cyltezo, etc.)

Etanercept (Enbrel) and biosimilars (Erelzi, Eticovo)

Infliximab (Remicade) and biosimilars (Inflectra, Renflexis, Avsola)

A class switch carries risk of treatment disruption and requires careful medical supervision. However, many TNF biosimilars are now on preferred formulary tiers and may actually be easier to access and less expensive than IL-6 inhibitors under certain insurance plans.

Oral JAK Inhibitors: An Alternative for RA Patients

For patients with RA, JAK (Janus kinase) inhibitors are oral alternatives to injectable biologics. These include:

Rinvoq (upadacitinib): Once-daily oral tablet. FDA-approved for RA, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, and Crohn's disease.

Olumiant (baricitinib): Once-daily oral tablet approved for RA and alopecia areata.

Xeljanz (tofacitinib): Oral JAK inhibitor for RA and ulcerative colitis. Comes with FDA boxed warnings for serious cardiac events, thrombosis, and malignancy in patients at cardiovascular risk.

JAK inhibitors carry their own risk profiles including increased infection risk, potential cardiovascular effects, and cancer risk in certain populations. Your rheumatologist will weigh these risks carefully.

Orencia (Abatacept): A T-Cell Pathway Alternative

Orencia (abatacept) works by a completely different mechanism — it modulates T-cell activation rather than blocking IL-6. It is approved for moderate-to-severe RA in adults and juvenile idiopathic arthritis in children. It is available as both an IV infusion (monthly) and a weekly SC injection. Abatacept may be a preferred alternative for patients with certain comorbidities or contraindications to IL-6 blockade.

Bridge Strategies While Waiting for Access

If you're waiting for Tyenne access to be restored and your symptoms are flaring, your doctor may recommend a short bridge therapy:

A short course of oral corticosteroids (prednisone) to control inflammation

Adjusting or adding conventional DMARDs (methotrexate, hydroxychloroquine, sulfasalazine)

NSAIDs for short-term symptom management

Before switching medications, make sure you've exhausted your options to find Tyenne. medfinder can search pharmacies near you to see which ones have Tyenne in stock, helping you avoid an unnecessary medication change due to access issues alone.

See also: How to find Tyenne in stock near you.